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γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain and 
dysfunction of GABA is related to several neurological and psychiatric disorders1. In order to 
understand the role of GABA in brain disorders, the GABAA receptor antagonist flumazenil has 
been used in Positron Emission Tomography (PET) studies2,3. [11C]Flumazenil is a well-
established PET tracer that has been used to, e.g., identify penumbral areas of infarction in 
stroke4, as well as assess neuronal damage in head injury5, epilepsy6, and Alzheimer’s disease7. 
In general, [11C]flumazenil is used as a marker for neuronal integrity and neuronal loss8,9. 
Neuronal loss is generally accompanied by an inflammatory process, especially in 
neurodegenerative diseases10,11. Interestingly, immune cells involved in neuroinflammation (i.e. 
microglia, astrocytes, infiltrating T-cells and macrophages) are also able to express GABAA 
receptors12–17, which play an important role in the activation of immune cells and the 
consequent release of anti- and pro-inflammatory cytokines and chemokines18. GABA appears 
to have a regulatory function in autoimmune diseases and during inflammatory responses to 
infections19. For example, it has been found that GABA acts as a powerful anti-inflammatory 
stimulus on immune cells in mouse models of inflammatory conditions such as rheumatoid 
arthritis20, diabetes type 121, and multiple sclerosis22.  
Therefore, the study of neuronal loss in brain disorders with [11C]flumazenil could be 
compromised by its binding to receptors expressed in activated immune cells. Consequently, a 
decrease in binding due to neuronal loss might be partially obscured by an increased binding 
of the tracer to these activated immune cells, leading to an incorrect interpretation of the results. 
Generally, the specific binding of [11C]flumazenil to the GABAA receptors can be quantified by 
pharmacokinetic modeling using arterial input functions23 or a reference tissue with low 
expression of the receptor as indirect input24. Although no brain region is completely free of 
GABAA receptors25,26, the pons has been used as a reference tissue 5,24,27. However, the use of the 
pons as the reference tissue may not be valid if an increase in GABAA receptor density is seen 
in this tissue due to the activation of immune cells.  
In this study, we evaluated if the presence of neuroinflammation results in increased 
[11C]flumazenil binding and, consequently, whether this affects the use of the pons as reference 
  
tissue for pharmacokinetic modeling. For this purpose, we used the herpes simplex encephalitis 
(HSE) rat model,  known to cause severe neuroinflammation in the pons and medulla28–30, and 
compared estimates of [11C]flumazenil binding determined from a reference based model to the 
plasma input derived parameters.  
Materials and methods 
Animals 
Male outbred Wistar-Unilever rats (n=19) were obtained from Harlan (Horst, The 
Netherlands). The rats were group housed in Makrolon cages on a layer of wood shavings, in a 
room with constant temperature (21±2°C) and 12 h light-dark regime. Standard commercial 
chow and water were available ad libitum. After inoculation, the rats were individually housed 
in independent ventilated cages. All animal experiments were performed according to the 
Dutch Law on Animal Experiments, and were approved by the Institutional Animal Care and 
Use Committee of the University of Groningen (DEC 6264B).  
The rats were randomly divided into two groups: control (n=10) and HSE (n=9). In 4 
rats from each group, the GABAA receptors were pre-saturated with 330 nmol of unlabeled 
flumazenil to determine non-specific binding (Table 1). 
Table 1. Overview of the groups, injected activity and mass.  
Group 
Body weight 
Day 0 (gr) 
Body weight 





Control (n=6) 243±22 [222-282] 281±25 [260-318] 65±28 [28-96] 3.4±2.5 [1.5-7.6] 
HSE (n=5) 246±13 [233-266] 267±27 [239-303] 57±18 [40-85] 4.1±3.1 [1.6-7.8] 
Control PS (n=4) 288±11 [274-301] 288±11 [274-301] 51±24 [22-72] 7.0±7.1 [2.0-17.1]
HSE PS (n=4) 251±9 [242-262] 293±10 [279-303] 47±10 [38-59] 6.6±6.6 [2.1-16.2]
Mean ± standard deviation [minimum – maximum]. HSE: Herpes simplex encephalitis. PS: pre-saturation. 
* These values represent the injected mass during tracer injection. Pre-saturation with 330 nmol of unlabeled flumazenil performed 5 min 







Herpes simplex encephalitis model  
Herpes simplex encephalitis was induced by intranasal inoculation with the herpes 
simplex virus type-1, obtained from a clinical isolate and cultured in Vero cells. The culture was 
assayed for plaque-forming units (PFU) per ml29. Rats were inoculated under light anesthesia 
(5% isoflurane mixed in medical air) by application of 50 µl of phosphate-buffered saline (PBS) 
with 0.5×107 PFU of virus (HSE group) or PBS only (control group) into each nostril. 
[11C]Flumazenil synthesis 
[11C]Flumazenil was synthesized as previously described31, with some modifications. In 
summary, [11C]methyltriflate was transferred with a helium gas flow (30 ml/min) into the 
reaction vial containing 0.5 mg of desmethyl-flumazenil (ABX  art.1700.0001) and 10 μL 1M 
NaOH dissolved in 300 μL of dry acetone at room temperature. After the trapping, the reaction 
mixture was heated at 60 oC for 1 min. Then, 0.7 ml of HPLC eluent was added (23% of 
acetonitrile in 25 mM aqueous NaH2PO4 at pH 3.5). The mixture was purified by HPLC over a 
μBondapak™ C18 125Å column (10μm, 7.8×300 mm, Waters) at a flow rate of 5 ml/min. The 
purified product with a retention time of 13-14 min was collected, diluted in 85 ml water and 
passed over an Oasis HLB 1cc cartridge (30 mg, Waters). The cartridge was washed twice with 
8 ml of saline, and eluted with 0.75 ml of ethanol and 4.5 ml of saline. The product was sterilized 
over a 0.22 μm LG filter, collected in a sterile vial with a 53±18% radiochemical yield. Quality 
control was performed using Waters Acquity H-class UPLC, with a Berthold Flow Star LB 513 
radioactivity detector and Waters Acquity UPLC C18 BEH phenyl Shield RP18 column (1.7 
µm, 3×50 mm) at 35 °C. The product was eluted with 20% acetonitrile in water at pH 2.0 
(adjusted with HClO4) at a flow rate of 0.6 ml/min. The UV signal was measured at a wavelength 
of 220 nm. The retention time of the precursor (desmethyl-flumazenil) was 1.3-1.6 min, and 
the retention time of [11C]flumazenil was 2.1-2.6 min. The radiochemical purity of 





PET procedure  
[11C]Flumazenil PET scans were acquired at day 6 or 7 post-inoculation28–30. Rats were 
anesthetized with 5% isoflurane (maintained at 1.5-2.2%) mixed with medical air at a flow of 
1.5-2 ml/min. A cannula was inserted in the femoral vein for tracer injection, and in the femoral 
artery for arterial blood sampling. The rats were then positioned into the small animal PET 
camera (Focus 220, Siemens Medical Solutions, USA) in a trans-axial position with their heads 
in the field of view. A transmission scan of 515 s was acquired using a Co-57 point source. 
Hereafter, [11C]flumazenil was injected over 1 min using an automatic pump at a speed of 1 
ml/min. A 60-min dynamic PET acquisition was started when the tracer entered the body. 
Unlabeled flumazenil, 330 nmol in 200 µl of 15% ethanol in saline, was intravenously injected 
5 min before tracer injection in the pre-saturated groups32. 
During the scan, 16 blood samples of 0.1 ml were taken (10, 20, 30, 40, 50, 60, 90, 120, 
180, 300, 450, 600, 900, 1800, 2700, and 3600 s). Larger blood samples of 0.6 ml were obtained 
at 2 or 3 of these time points for metabolite analysis. After collection of each blood sample, an 
equivalent volume of heparinized saline was injected to prevent large changes in blood pressure. 
A 25 µl aliquot of whole blood was extracted from each sample for radioactivity measurement. 
The remaining volume of the sample was centrifuged at 13,000 rpm (15,996×g) for 8 min and 
25 µl of plasma was taken for radioactivity measurement. The radioactivity in blood and plasma 
was measured in a gamma counter (LKB-Wallac, Finland). 
PET image processing  
The list-mode data from the emission scan was reconstructed into 21 time frames (6×10, 
4×30, 2×60, 1×120, 1×180, 4×300, and 3×600 s). Emission sinograms were iteratively 
reconstructed (OSEM2D, 4 iterations and 16 subsets) after being normalized and corrected for 
attenuation and radioactivity decay. The PET images were analyzed with PMOD v3.7 software 
(PMOD Technologies Ltd., Switzerland). Automatic registration of the scans was performed 
using a [11C]flumazenil template33, and bilateral volumes of interest (VOI) were selected for 
regions with high GABAA expression (the frontal and cerebral cortices, and hippocampus) and 
low GABAA expression (cerebellum, medulla and pons), in addition to the medulla and pons 
that are most affected in the HSE rat model28–30 (Figure S1). Time-activity curves (TACs) were 
  
generated for each VOI and expressed as the standardized uptake value (SUV), by correcting 
the radioactivity concentration in the brain regions for the injected dose and body weight. 
Metabolite analysis 
Metabolite analysis was performed in plasma samples collected at 5 (n=6), 10 (n=2), 15 
(n=7), 30 (n=4), 45(n=2) or 60 min post injection (n=5). Given the volume of blood needed for 
metabolite analysis and the limitations in the amount of blood that can be taken from a single 
rat, only 2 or 3 time-points per rat were selected for metabolite analysis. The plasma was diluted 
with an equivalent volume of acetonitrile, mixed with a vortex for 1 min and then centrifuged 
for 3 min at 5,300 rpm (3,030×g). The supernatant was filtered through a Millipore filter 
(Millex-HV 4 mm syringe filter, pore 0.45 µm). An equivalent volume of water for injection was 
added and the volume was adjusted to 1 ml with HPLC mobile phase. The solution was analyzed 
by HPLC using an Alltima RP-C18 column (5 µm, 10×250 mm) and a mobile phase consisting 
of acetonitrile/1mM H3PO4 (25/75) at a flow of 5 ml/min. In total 48 fractions of 30 s were 
collected and measured in the gamma counter. The percentage of metabolites was calculated by 
dividing the activity of the metabolites by the total amount of radioactivity in all fractions 
combined. No statistical differences were found between the metabolite curves of the two 
groups. Therefore, all metabolite data was used to obtain a single population-based curve fitted 
with a single exponential function. 
Pharmacokinetic modeling 
Pharmacokinetic analysis was performed in PMOD v3.7 (PMOD Technologies Ltd, 
Switzerland). The scans were analyzed using the two-tissue compartment model (2TCM)3,25,27. 
Blood and metabolite corrected plasma curves were used as input function, with a fixed blood 
volume of 5%. 
The volume of distribution (VT) was used as the main outcome parameter to determine 
if the presence of neuroinflammation resulted in an increased binding of [11C]flumazenil. In the 
non-saturated groups, the non-displaceable binding potential (BPND) was indirectly computed 
from the ‘distribution volume ratio’ (DVR) from the 2TCM according to the formula: BPND = 
  
DVR – 1 = (VT / VT reference) – 134. The BPND was also directly determined using the Simplified 
Reference Tissue Model (SRTM) 24, with the pons as the reference tissue. 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 22. Differences between 
TACs of blood and plasma were explored by means of the Generalized Estimating Equations 
model35, including group and time as predictive variables in the model. The unstructured 
correlation matrix was selected according to the quasi-likelihood under the independence 
model information criterion value, and the Wald test was used to report the p-values. Group 
differences in injected dose, injected mass, VT and BPND values were analyzed by one-way 
ANOVA and Student’s t-test. The Pearson’s correlation coefficient was used to analyze the 
correlations. The existence of bias in the BPND values was further explored by Bland-Altman 
plot. Probability (p) values <0.05 were considered significant. 
Results 
Descriptive statistics 
An overview of the groups, and the injected activity and mass of [11C]flumazenil is given 
in Table 1. No statistically significant differences were found between groups in the injected 
activity or injected mass. 
The PET images (Figure 1) showed higher uptake in the gray matter than in white 
matter. No differences were observed in the [11C]flumazenil uptake between control and HSE 
rats, while there was a clear decrease in brain uptake in pre-saturated rats. [11C]Flumazenil 
TACs (Figure 2) of the pons (low GABAA receptor expression) showed highest uptake 1-2 min 
after tracer injection, while uptake in the frontal cortex (high GABAA receptor expression) was 
highest about 4-7 min after injection. No statistically significant differences were found between 
the TACs of control and HSE rats. Pre-saturation with unlabeled flumazenil resulted in a lower 
peak value in the first minute after injection followed by a faster washout, resulting in stable 
uptake about 10 min after injection. A statistically significant lower TAC (p<0.001) was found 
in the pons and frontal cortex for both the control and HSE rats, when compared with its 
corresponding pre-saturated group. 
  
 
Figure 1. Representative [11C]flumazenil PET brain images (30-60 min after injection) of a control rat , rat with 
herpes simplex encephalitis (HSE), and control and HSE rats pre-saturated with unlabeled flumazenil. 
 
Figure 2. Average [11C]flumazenil time-activity curves of the pons (low GABAA receptor expression) and frontal 
cortex (high GABAA receptor expression). Data is expressed as the standardized uptake value (mean ± SD). HSE: 
herpes simplex encephalitis. 
[11C]Flumazenil uptake in whole blood and plasma peaked around 40 s after injection 
(Figure 3A) and only about 15% of intact [11C]flumazenil was present 10 min after injection 
(Figure 3B). No statistically significant differences were found between groups in whole blood 
uptake, metabolite corrected plasma uptake, or metabolism. 
  
 
Figure 3. (A) [11C]Flumazenil time-activity curve for whole blood and metabolite corrected plasma (mean ± SD), 
(B) and the percentage of radioactive metabolites in plasma. 
 
Distribution volume (VT) 
To determine if the presence of neuroinflammation increased [11C]flumazenil binding, 
the VT was calculated with the 2TCM. The highest VT values were found in the frontal cortex, 
while the lowest were found in the medulla and pons (Table 2). No statistically significant 
differences were found between the control and HSE groups in any of the brain regions. In HSE 
rats and controls, pre-saturation with unlabeled flumazenil caused a statistically significant 
reduction in the VT in all the brain regions (p<0.001) when compared with the corresponding 
non-saturated groups. No differences were found between control and HSE pre-saturated 
groups. 
Table 2. [11C]Flumazenil VT (mean ± standard error) obtained by two-tissue 
compartment modeling. 
    Pre-saturated 
Brain Region Control HSE Control HSE 
Frontal cortex 7.68 ±0.30 7.86±0.70 0.92±0.27* 0.98± 0.07* 
Cerebral cortex 6.85 ±0.29 7.03±0.62 0.95±0.26* 0.96± 0.06* 
Hippocampus 6.72 ±0.20 6.97±0.61 0.86±0.23* 0.84± 0.07* 
Cerebellum 4.29 ±0.17 4.39±0.40 0.81±0.23* 0.83± 0.06* 
Pons 2.96 ±0.07 3.22±0.32 0.78±0.21* 0.90± 0.05* 
Medulla 2.48 ±0.06 2.74±0.29 0.78±0.22* 0.90± 0.07* 
*p<0.001 for the groups pre-saturation with flumazenil when compared with its 
correspondent non-saturated group. 2TCM: two-tissue compartment model; HSE: 
Herpes simplex encephalitis. 
  
Non-displaceable binding potential (BPND) 
No statistically significant differences were found in the BPND values (Table 3) between 
control and HSE groups in any of the brain regions. The BPND values (Figure 4) obtained directly 
from the SRTM had a high correlation with the DVR – 1 values from 2TCM (r2=0.98, p<0.001). 
However, BPND from SRTM were consistently lower than those from the 2TCM (slope = 0.80). 
This negative bias (-0.15±0.15) of the BPND values directly derived from the SRTM was also 
observed in the Bland-Altman analysis. A region-dependent bias was found (Figure 4B), with 
high-binding regions presenting the largest differences (e.g. cortical regions). No statistical 
difference was observed between control and HSE groups in the bias of the BPND values (Figure 
4C). 
 
Figure 4. (A) Linear regression and (B, C) Bland-Altman plots for non-displaceable binding potential (BPND) values obtained 


















Table 3. Non-displaceable binding potential (BPND, mean ± 
standard error) obtained from the two-tissue compartment 
model and the simplified reference tissue model using the 
pons as the reference tissue. 
Brain Region Model Control HSE 
Frontal cortex SRTM 1.29±0.05 1.22±0.06 
 2TCM 1.60±0.09 1.45±0.05 
Cerebral cortex SRTM 1.01±0.04 0.98±0.07 
 2TCM 1.31±0.07 1.20±0.07 
Hippocampus SRTM 1.03±0.04 1.00±0.08 
 2TCM 1.27±0.05 1.18±0.08 
Cerebellum SRTM 0.40±0.01 0.33±0.02 
 2TCM 0.45±0.04 0.37±0.02 
Medulla SRTM -0.13±0.01 -0.13±0.01 
 2TCM -0.16±0.01 -0.15±0.01 
SRTM: simplified reference tissue model; 2TCM: two-tissue 
compartment model; HSE: Herpes simplex encephalitis. 
 
Discussion 
The aim of the present study was to explore whether a neuroinflammatory process 
would influence the [11C]flumazenil binding in the pons, therefore compromising its use as 
reference tissue in pharmacokinetic analysis. The results obtained showed that the presence of 
neuroinflammation does not affect the binding of [11C]flumazenil to the GABAA receptors. 
The use of the pons as reference tissue has already been studied in healthy volunteers 
and several neurological conditions5,27,36. However, to the best of our knowledge, no studies have 
been performed in a model that presented inflammation in the reference tissue. Astrocytes, 
microglia and T-lymphocytes are known to express GABAA receptors in their cell membrane. 
These immune cells participate in the process of neuroinflammation, which is accompanied by 
overexpression of GABA receptors12,19. In fact, growing evidence shows the protective effects of 
GABA in the central nervous system and in the periphery19. Due to the close relationship 
between the immune and GABA systems, we hypothesized that the uptake of [11C]flumazenil 
would be higher in inflamed brain regions. The HSE rat model was chosen because the tropism 
of HSV-1 evocated strong acute neuroinflammation in the pons, which has been previously 
confirmed by immunohystochemical staining of microglia cells29 and by PET imaging using an 
  
array of TSPO radioligands 28–30,37. It has to be mentioned that the activation of microglia cells 
in the HSE model does not necessarily imply changes in GABAA expression, which have not 
been confirmed by immunohystochemical staining, as our main aim was to determine if 
[11C]flumazenil  pharmacokinetic modeling was affected by inflammation. 
In the present study, no significant alterations were found in the [11C]flumazenil TACs 
or the VT values of any brain region between healthy animals and the HSE group. These results 
seem to support the validity of reference tissue based models even in the presence of an acute 
severe inflammatory reaction. Nevertheless, it cannot be excluded that a different immune 
challenge may induce a different inflammatory response with a different regulation of the 
GABAergic system. 
Possible changes in the GABAA complex, due to the administration of isoflurane as 
anesthetic drug38–41, might be considered as a limitation in our study. Moreover, a study on mice 
has shown an increase in [18F]flumazenil binding in the animals anesthetized with isoflurane42. 
This effect encourages caution in the interpretation of the data involving this anesthetic. 
However, in the present study, all animals underwent the same anesthetic procedure, and were 
exposed to similar amounts of isoflurane. Therefore, an effect of isoflurane could be expected 
in GABAA receptors of all animals, which should not interfere in group comparisons. 
While the pons is a well-accepted reference tissue, it is not entirely devoid of GABAA 
receptors43–45. In fact, no brain regions can be considered completely GABAA receptor free25,26. 
In the present study, a statistically significant reduction of the VT value and the TACs was found 
in all brain regions, including the pons, when the animals were treated with unlabeled 
flumazenil 5 min before starting the scan, when compared with the corresponding group 
without pre-saturation. Similar results were previously reported in displacement studies32. 
Based on these results, the pons should be considered as a ‘pseudo-reference’ tissue, as it is not 
devoid of the receptor of interest, but receptor expression does not significantly differ between 
conditions. Interestingly, in the present study the medulla of non-saturated groups showed 
statistically lower VT values than the pons (p<0001). This result opens the possibility to further 
explore this region, or the whole brainstem, as an alternative ‘pseudo-reference tissue’ in the 
quantification methods in rat studies. 
  
 
Figure S1. Bilateral volumes of interest were selected with high GABAA expression (frontal and cerebral cortices, 
and hippocampus) and low GABAA expression (cerebellum, medulla and pons). 
 
The use of reference tissue based models simplifies the scanning procedures, allowing 
the quantification of BPND values without the acquisition of blood and plasma samples to obtain 
the input functions. These models are preferred as they are less invasive27 and are especially 
useful in longitudinal study designs.  
In the present study, however, a region-dependent underestimation of the BPND 
obtained with the SRTM was observed, which was not different between control and HSE 
groups. This bias was already reported to be dependent upon both blood flow and receptor 
density43. In our results, no differences in the ‘pseudo-reference’ tissue of the pons were 
observed between groups in either the K1, k2 or K1/k2 values. Therefore, it can be assumed that 
the bias was mostly related to receptor density. 
While this underestimation must be considered carefully, the high correlation found in 
the BPND values obtained using the arterial input function and the reference tissue based 
method, indicate that the latter can be used for future [11C]flumazenil studies. 
Conclusion 
The acute neuroinflammatory reaction in the brainstem of the herpes simplex 
encephalitis rat model did not significantly affect [11C]flumazenil binding in the pons, as 
measured by PET imaging. Although the pons was found not to be devoid of GABAA receptors, 
it can be a valid pseudo-reference tissue for advanced quantitative methods (i.e. 
pharmacokinetic modeling), even in the presence of neuroinflammation.  
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